← Eichor
Study identifier: NCT04464122 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Condition: Neuroendocrine Tumors · Neuroendocrine Neoplasm · Neuroendocrine Tumor Grade 1  ·  Sponsor: University of Roma La Sapienza

PhaseN/A
Planned participants60
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

This is a multicentre, controlled, observational prospective study on new biomarkers, as immune profiling, angiogenetic markers and circRNA from TEPs in the diagnosis and in the evaluation of treatment response in pulmonary and gastro-entero-pancreatic NENs.

This description comes directly from the study's public registry record.

Talk to the study team

Andrea M Isidori, MD, PhD  ·  +390649970540  ·  andrea.isidori@uniroma1.it

Elisa M Giannetta, MD, PhD  ·  +390649970540  ·  elisa.giannetta@uniroma1.it

Always discuss trial participation with your own doctor first.

Locations (1)

Andrea M IsidoriRome, Italy, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04464122